Inhibitor Therapeutics (Inhibitor Therapeutics) Cash And Cash Equivalents : $7.68 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics Cash And Cash Equivalents?

Inhibitor Therapeutics's quarterly cash and cash equivalents declined from Sep. 2023 ($9.54 Mil) to Dec. 2023 ($8.84 Mil) but then stayed the same from Dec. 2023 ($8.84 Mil) to Mar. 2024 ($7.68 Mil).

Inhibitor Therapeutics's annual cash and cash equivalents increased from Dec. 2021 ($0.03 Mil) to Dec. 2022 ($11.95 Mil) but then declined from Dec. 2022 ($11.95 Mil) to Dec. 2023 ($8.84 Mil).

Inhibitor Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Inhibitor Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics Cash And Cash Equivalents Chart

Inhibitor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.80

0.08

0.03

11.95

8.84

Inhibitor Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															10.78	10.10	9.54	8.84	7.68

Inhibitor Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Inhibitor Therapeutics (OTCPK:INTI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Inhibitor Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 West Platt Street, Suite 200, Tampa, FL, USA, 33606-2173

Website

https://www.inhibitortx.com

Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.

Executives

Black Robe Capital Llc	10 percent owner	900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii	10 percent owner	1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman	director, 10 percent owner	1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii	10 percent owner	C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc	10 percent owner	12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez	director	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty	10 percent owner, officer: See Remarks	C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd	10 percent owner	1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara	officer: CFO and Treasurer	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie	director	4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin	director	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab	director, officer: Chairman of the Board	C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606